GlassScriptPhysician profile
Paula S Sprow
NPI 1396720124
$3,637.11
in general payments reported to CMS, 2019-2025
44 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $759 · 2023: $870 · 2024: $826 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $468.34 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $425.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.68 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $220.12 | 2021-2025 | |
| Amgen INC. | $151.64 | 2021-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $144.71 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $137.09 | 2021-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $119.83 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $87.61 | 2023-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $81.88 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $77.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $76.52 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $74.96 | 2023-2025 | Rexulti |
| Organon LLC | $60.61 | 2021-2025 | Nexplanon |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Sprow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.